Trial data shows AstraZeneca’s COVID-19 vaccine was highly effective
AstraZeneca announced today, that interim trial data has shown it’s COVID-19 vaccine candidate AZD1222, developed in collaboration with the University
Read more
Clinical Trials
Moderna’s COVID-19 vaccine shows efficacy of 94.5% in Phase 3 trial
Moderna announced its vaccine candidate against COVID-19 named mRNA-1273, has met Phase 3 study statistical criteria with a vaccine efficacy
Read more
Pfizer and BioNTech announce important COVID-19 vaccine breakthrough
Pfizer and BioNTech have announced their mRNA-based vaccine candidate for COVID-19, tested in a Phase 3 study involving 43,538 participants,
Read more
AstraZeneca receives FDA authorisation to resume COVID-19 vaccine trial
AstraZeneca has confirmed that the U.S. FDA has authorised the resumption of Phase III clinical trials of the COVID-19 AZD1222
Read more
Lilly’s Mirikizumab shows reduction of Intestinal Inflammation in Crohn’s Disease
Eli Lilly and Company revealed on Monday, new efficiency and safety results from the Phase 2 SERENITY trial assessing Mirikizumab
Read more
Abbott enrolls first patient in SCS/CMM trial to treat chronic low back pain
Abbott declared the first patient has been enrolled in the DISTINCT study (Dorsal spInal cord STImulatioN vs mediCal management for
Read more
J&J Covid-19 Vaccine produces a strong neutralizing antibody response
Interim analysis of the J&J COVID-19 vaccine candidate (JNJ-78436735) in the ongoing Phase 1/2a clinical trial has shown that a
Read more
New data reveals Roche’s OCREVUS is highly effective for RRMS
Swiss pharma giant Roche announced today new data that demonstrates OCREVUS® (ocrelizumab) is a highly effective treatment option for people
Read more
Oxford & AstraZeneca pause COVID-19 trial as participant falls ill
Phase 3 clinical trials for the COVID-19 vaccine named AZD1222, developed by AstraZeneca and Oxford University, have been paused after
Read more
Lilly starts Phase 3 Trial of monoclonal antibody for COVID-19 prevention
Eli Lilly and Company announced the start of BLAZE-2, a Phase 3 study of the monoclonal antibody LY-CoV555 vaccine candidate
Read more